With the upmost respect the forward PE ratio has nothing to do with how long a drug has been on market and more about sales growth. Even if only 50% of identified North American patients day on Daybue that’s an extra 1000-1250 patients on the low end. Then you add you Canada (modest amount). After that you add on European approval (potentially larger market than North America - with lower price), then there’s Japan and emerging markets LATM, etc all to come later.
Go look at biotech companies expected to grow earnings by 20% or more for years on end and tell me what their forward earnings ratios are?
Neuren Media and Analyst Coverage, page-1190
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.05 |
Change
0.600(2.93%) |
Mkt cap ! $2.709B | |||
| Open | High | Low | Value | Volume |
| $20.56 | $21.55 | $20.54 | $10.13M | 479.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 398 | $21.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.06 | 251 | 9 |
View Market Depth
| Last trade - 15.44pm 16/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |